VRx-3996 (formerly CHR-3996)

Collapse Summary General Information
Company Viracta Therapeutics Inc.
DescriptionHistone deacetylase (HDAC) inhibitor
Molecular Target Histone deacetylase (HDAC)
Mechanism of ActionHistone deacetylase (HDAC) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationLymphoma
Indication DetailsTreat Epstein-Barr virus (EBV)-associated lymphoid malignancies
Regulatory Designation
PartnerNantKwest Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/04/2017

Undisclosed

Undisclosed

Undisclosed

11/30/2016

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today